Search Medical Condition
Please enter condition
Please choose location from dropdown

New Lambton Heights, Australia Clinical Trials

A listing of New Lambton Heights, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (116) clinical trials

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Study details: Participants will be allocated to either experimental or control group in a 2:1 ratio by chance (randomly). Patients assigned to the experimental group will receive a course of nivolumab via intravenous infusion (240 mg on days 1 and 15 every 28 days for cycles 1-4; then 480 mg …

Phase

0.0 miles

Learn More »

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

This is a randomized, double-blind, parallel group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of CNM-Au8 in stable RRMS patients who have Chronic Optic Neuropathy (residual deficits of conduction velocity in the visual pathway) evidence by low contrast letter acuity deficits at Screening. Patients will be screened over a …

Phase

0.0 miles

Learn More »

Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)

The WiSE-CRT System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

Phase N/A

0.0 miles

Learn More »

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF. All patients will remain on their CF standard-of-care treatments over the trial duration. The goal for the treatment with LAU-7b in CF is to …

Phase

0.0 miles

Learn More »

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Phase

0.0 miles

Learn More »

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

Phase

0.0 miles

Learn More »

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

This study enrolls participants with high risk NMIBC FGFR mutations or fusions. Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor with demonstrated clinical activity in participants with solid tumors, including urothelial carcinoma, with alterations in the FGFR pathway. In Cohort 1, participants will be randomized to erdafitinib …

Phase

0.0 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

0.0 miles

Learn More »

Beta-Lactam InfusioN Group Study

Aim To conduct a multicentre randomised, controlled trial (RCT) to determine whether continuous infusion of a beta-lactam antibiotic (piperacillin-tazobactam or meropenem) results in decreased all cause Day 90 mortality compared with intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis. Hypothesis The BLING III Study will test the hypothesis …

Phase N/A

0.0 miles

Learn More »

Study of Kidney Tumors in Younger Patients

PRIMARY OBJECTIVES: I. Classify patients with renal tumors by histological categorization, surgico-pathological stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity for chromosomes 1p and 16q, to define eligibility for a series of therapeutic studies. (Loss of heterozygosity [LOH] testing discontinued as of April 2014) II. …

Phase N/A

0.0 miles

Learn More »